跳至主要内容
临床试验/NL-OMON54253
NL-OMON54253已完成不适用

SabiliTy and FeAsiBILIty of a personalised, web-based Education and self-management approach for patients with chronic Heart Failure across four European sites - STABILISE HF

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • Adults (>=18 years) that own a device where SanaCoach heart failure can be
  • Diagnosis of chronic heart failure according to ESC 2016 guidelines (HFrEF =
  • LVEF <40%, HFmrEF = LVEF 40-49%, HFpEF = LVEF >= 50%), based on
  • echocardiographic or MRI findings within the last year or considered stable
  • Ability and willingness to give written informed consent and to comply with
  • the requirements of the study
  • UPDATE-HF sub study:
  • Patient's inclusion criteria
  • Be enrolled in the STABILISE-HF study
  • Patient may not already use SanaCoach or have used it in the past
  • Willingness to have the interview recorded and transcribed
  • Sufficient Dutch language skills to answer questions
  • Ability and willingness to give written informed consent and to comply with
  • the requirements of the study
  • Patient*s relatives/informal caregivers inclusion criteria
  • Relative/informal caregiver of a patient diagnosed with HF who has already
  • been enrolled in the STABILISE-HF study
  • Adults (>=18 years)
  • Sufficient English language skills to answer questions
  • Ability and willingness to give written informed consent and to comply with
  • the requirements of the study

排除标准

  • A potential subject who meets any of the following criteria will be excluded
  • from participation in this study:
  • Patients without access to a device where SanaCoach heart failure can be used
  • Uncontrolled or serious disease, or any medical or surgical condition, that
  • may either interfere with participation in the clinical study, and/or put the
  • subject at significant risk (according to investigator's judgment) if he/she
  • participates in the clinical study.
  • Patients that have been hospitalised for heart failure within the last 30
  • An underlying known disease, or surgical, physical, or medical condition
  • that, in the opinion of the investigator might interfere with interpretation of
  • the clinical study results.
  • Treatment with other investigational products or devices within 30 days or
  • five half-lives of the screening visit, whichever is longer.
  • Planned use of other investigational products or devices during the course of
  • Any condition that according to the investigator could interfere with the
  • conduct of the study, such as but not limited to:
  • a. Subjects who are unable to communicate or to cooperate with the
  • investigator.
  • b. Unable to understand the protocol requirements, instructions and
  • study-related restrictions, the nature, scope, and possible consequences of the
  • c. Unlikely to comply with the protocol requirements, instructions, and
  • study-related restrictions (eg, uncooperative attitude, inability to return for
  • follow-up visits (as parts of standard care), and improbability of completing
  • the study).
  • d. Have any medical or surgical condition, which in the opinion of the
  • investigator would put the subject at increased risk from participating in the
  • e. Persons directly involved in the conduct of the study.

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验